Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$88.36M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$89.89M
EBITDA Margin
-35.83%
TTM Avg
-39.56%
3Y Avg
-111.97%
5Y Avg
-250.85%
Market Cap
$90.22M
EBITDA Margin
-3260.14%
TTM Avg
-6375.74%
3Y Avg
-6375.74%
5Y Avg
-6375.74%
Market Cap
$88.21M
EBITDA Margin
15.84%
TTM Avg
9.89%
3Y Avg
0.86%
5Y Avg
4.00%
Market Cap
$91.36M
EBITDA Margin
-19.79%
TTM Avg
-29.84%
3Y Avg
-150.95%
5Y Avg
-150.95%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PMV Pharmaceuticals, Inc. (PMVP) | $89.33M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $89.02M | 23.63% | 23.21% | 8.97% | 9.09% |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $88.36M | N/A | N/A | N/A | N/A |
| electroCore, Inc. (ECOR)vs › | $89.89M | -35.83% | -39.56% | -111.97% | -250.85% |
| Rallybio Corporation (RLYB)vs › | $90.22M | -3260.14% | -6375.74% | -6375.74% | -6375.74% |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 15.84% | 9.89% | 0.86% | 4.00% |
| Biomea Fusion, Inc. (BMEA)vs › | $91.30M | N/A | N/A | N/A | N/A |
| Equillium, Inc. (EQ)vs › | $91.36M | -19.79% | -29.84% | -150.95% | -150.95% |
| Conexeu Sciences Inc. (CNXU)vs › | $91.98M | N/A | N/A | N/A | N/A |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $92.47M | 5.05% | 6.33% | 5.80% | 5.80% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
